Imipramine Pamoate

CHEMBL3989845 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
949.2 g/mol
LogP
Phase
4

This pamoate salt of imipramine provides extended-release characteristics suitable for once-daily dosing in the treatment of depression and anxiety. The pamoate salt reduces gastrointestinal side effects and provides sustained drug levels throughout the day. Like other imipramine formulations, it inhibits neurotransmitter reuptake and carries the same cautions regarding cardiac and anticholinergic effects.

Khối lượng phân tử

949,2000 g/mol

TPSA

128,00 Ų

Lĩnh vực điều trị

Cơ chế tác dụng

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O

InChI

InChI=1S/C23H16O6.2C19H24N2/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;2*1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2*3-6,8-11H,7,12-15H2,1-2H3

Molecular Formula

C61H64N4O6

HBD / HBA

4 / 10

Liên kết có thể quay

12

Nguyên tử nặng

71

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This pamoate salt of imipramine provides extended-release characteristics suitable for once-daily dosing in the treatment of depression and anxiety. The pamoate salt reduces gastrointestinal side effects and provides sustained drug levels throughout the day. Like other imipramine formulations, it inhibits neurotransmitter reuptake and carries the same cautions regarding cardiac and anticholinergic effects.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Imipramine Pamoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989845. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 24904. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.